Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toxaphene is a complex synthetic mixture of over 670 chlorinated camphenes and related bicyclic terpenes that was historically utilized as an organochlorine pesticide and veterinary acaricide. Developed in the 1940s, it became one of the most heavily used insecticides in the United States, primarily applied to cotton crops and used to control ectoparasites such as mange, lice, and ticks on livestock. Toxaphene acts as a noncompetitive antagonist at the GABA-A receptor-associated chloride channel, leading to central nervous system hyperexcitability, tremors, and convulsions. Due to its high persistence in the environment, bioaccumulation in aquatic and terrestrial food chains, and potential carcinogenicity, toxaphene was banned in the United States in 1990 and globally restricted under the 2001 Stockholm Convention on Persistent Organic Pollutants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on toxaphene.